Pharma in silica’s precision chemotherapy attacks solid tumors while sparing patients painful, maiming and costly adverse effects imposed by current chemo. OpPacli™ is fifteen months to FDA Phase Ib/IIa 515(b)(2) clinical trial against NSCLC. In 2028, the nanocarrier platform will enable pharmas to capture the chemo drugs US$ 25B market.